

Concept course „Cell Biology“: 551-0326-00L

Spring semester 2017

Lipid metabolism: Part II


- I. Metabolic dysfunction and hepatic steatosis
- II. The lipogenic phenotype in cancer pathogenesis



Dr. Werner Kovacs

ETH Zürich, Institute of Molecular Health Sciences, HPL H16

werner.kovacs@biol.ethz.ch



Wild-type

Perilipin knockout

ob/ob


Obesity

- Obesity: Having a very high amount of body fat in relation to lean body mass, or Body Mass Index (BMI) of 30 or higher.
- Body Mass Index (BMI): a measure of an adult's weight in relation to his or her weight, specifically the adult's weight in kilograms divided by the square of his or her height in meters. BMI is used to assess the extent of general obesity.
- Waist-to-hip-ratio (WHR): parameter for central obesity (apple-shaped or pear-shaped obesity)
- Obesity is a complex trait, driven by the interaction between genetic and environmental factors.

Obesity Trends* Among U.S. Adults


BRFSS, 1990, 1998, 2006

(*BMI ≥ 30 , or about 30 lbs. overweight for 5'4" person)



Fat distribution influences risks associated with obesity in humans

normal BMI
normal WHR




high BMI
low WHR

high BMI
high WHR

Lipid and glucose homeostasis under different physiologic conditions

Satiety, Resting

Insulin



FFA β oxidation
FFA synthesis
Glycolysis



FFA β oxidation
FFA synthesis
Glycolysis
Glycogen synthesis
Glycogenolysis



Lipolysis
TAG synthesis
FFA synthesis
Glycolysis



TAG synthesis
FFA synthesis
FFA β oxidation
Keton body formation
Glycolysis
Gluconeogenesis
Glycogen synthesis
Glycogenolysis

Starvation, Exercise, Fight and Flight

Glucagon and/or Adrenalin



FFA β oxidation
FFA synthesis
Glycolysis



FFA β oxidation
FFA synthesis
Glycolysis
Glycogen synthesis
Glycogenolysis




Lipolysis
TAG synthesis
FFA synthesis
Glycolysis




TAG synthesis
FFA synthesis
FFA β oxidation
Keton body formation
Glycolysis
Gluconeogenesis
Glycogen synthesis
Glycogenolysis

Model of lipid flux through the liver




The disease spectrum of nonalcoholic fatty liver disease




Hepatic lipid metabolism in steatosis and steatohepatitis


A Forces regulating hepatic lipid homeostasis






B Dysregulation of hepatic lipid homeostasis leading to steatosis




C Dysregulation of hepatic lipid homeostasis leading to steatohepatitis



Selective insulin resistance in the liver produces a more severe metabolic defect than total insulin resistance



Metabolic pathways leading to the synthesis of triglycerides in the liver





Transgenic mice expressing truncated SREBP-1a



Wild-type




Transgenic
SREBP-1a 460



Livers from wild-type and transgenic mice expressing truncated dominant-positive SREBP-1a, -1c, and -2



Horton et al., J. Clin. Invest. (1998)




Wild-type


Transgenic
SREBP-1c436

Transgenic
SREBP-1a460


Shimano et al., J. Clin. Invest. (1997)

Model of the SREBP and miR-33 circuit






ChREBP and Mlx protein structures




NES: nuclear export signal

NLS: nuclear localization signal



ChREBP localization in glucose-starved mouse hepatocytes






ChREBP localization under low and high glucose concentrations

3 h




6 h

12 h


5.5 mM glucose




27.5 mM glucose




Subcellular localization of GFP-ChREBP under low or high glucose




Nutrient/hormone-mediated changes in protein phosphorylation determine ChREBP transactivity



Transcriptional regulation of hepatic lipogenesis by insulin and glucose via ChREBP, SREBP-1c, and LXR




ChREBP knockdown in liver



HCHO: high-carbohydrate diet

Summary of ChREBP knockdown in liver




LIPID METABOLISM IN CANCER

A limited set of phenotypes exists in virtually all aggressive cancers:



- Metabolic reprogramming in tumors occurs as a consequence of mutations in cancer genes and alterations in cellular signaling.
- Aerobic glycolysis (Warburg effect): Cancer cells consume high amounts of glucose and produce lactic acid; provides cancer cells growth advantages in the tumor microenvironment.
- Increased glutamine metabolism; glutamine-derived α -ketoglutarate contributes to the production of citrate.
- High rate of energy-consuming processes driving increased protein synthesis (e.g., mTOR pathway) and more active DNA synthesis.
- **Increased *de novo* fatty acid synthesis, which is functionally related to the glycolytic pathway (glycolysis provides energy and precursors for FA synthesis).**

Tumors as complex tissues


The Reductionist View



The tumor microenvironment



Core of Primary Tumor
microenvironment





Invasive Tumor
microenvironment




Metastatic Tumor
microenvironment





Whole-body lipid metabolism and cancer



The lipogenic phenotype in cancer pathogenesis




Clear cell renal cell carcinoma (ccRCC)




Colon cancer

Fat cells remodel the microenvironment around pancreatic tumors

- PDAC: pancreatic ductal adenocarcinoma
- Obesity is a major risk factor for PDAC
- PDAC is fourth most-common cause of cancer-associated death




Fat cells remodel the microenvironment around pancreatic tumors




- Adipocytes, immune cells and pancreatic stellate cells signal through IL-1 β and the AT1 angiotensin receptor to drive migration of neutrophils to the tumor microenvironment
- This increases the inflammatory and fibrotic response in the tumor microenvironment
- Denser cellular microenvironment puts extra mechanical tension on the tissue and may restrict blood-vessel perfusion
- Associated with poor response to chemotherapy and poor prognosis
- Depletion of neutrophils or blocking activity of IL-1 β reduce cancer progression

Lipids can promote different aspects of cancer development



Cellular fatty acid metabolism



FA, fatty acid

LPA, lysophosphatidic acid

PA, phosphatidic acid

MAG, monoacylglycerol

DG, diacylglycerol

TG, triacylglycerol

ACLY: ATP citrate lyase

ACC: acetyl-CoA carboxylase

FASN: fatty acid synthase

ACS: fatty acid-CoA ligase

MCD: malonyl-CoA decarboxylase

CIC, citrate carrier

CPT1: carnitine palmitoyl transferase

GPAT: glycerol-3-phosphate acyltransferase

AGPAT: acylglycerolphosphate acyltransferase

PAP: phosphatidic acid phosphohydrolase


DGAT: diacylglycerol acyltransferase

ATGL: adipose triglyceride lipase

HSL: hormone sensitive lipase

MAGL: monoacylglycerol lipase

Free fatty acids and tumorigenesis




ClC, citrate carrier

DGAT: diacylglycerol acyltransferase


MAGL: monoacylglycerol lipase



Two main pathways regulate the expression of tumor-associated FASN



ER, oestrogen receptor
E₂, oestradiol
AR, androgen receptor
A, androgens
PR, progesterone receptor
P, progestins



USP2a, ubiquitin-specific protease 2a


De novo fatty acid synthesis

- Two sources: exogenously-derived (dietary) FAs and endogenously-synthesized FAs
- Biosynthesis is catalysed by the multifunctional, homodimeric fatty acid synthase (FASN)
- Predominant product of FASN is palmitate (C16:0)
- In well-nourished individuals the role of FASN is of minor importance owing to sufficient levels of dietary fat.
- Most normal cells and tissues, even those with high cellular turnover, seem to preferentially use circulating lipids for the synthesis of new structural lipids.
- In normal conditions FASN converts excess carbohydrate into FAs that are then esterified to storage TAGs.
- De novo FA synthesis is very active during embryogenesis and in fetal lungs (production of lung surfactant).

De novo fatty acid synthesis




- A wide variety of tumors and their precursor lesions undergo exacerbated de novo biogenesis of FAs irrespective of the levels of circulating lipids.
- Neoplastic lipogenesis is reflected by significantly increased activity and coordinate expression of several lipogenic enzymes in tumor cells [e.g., FASN, ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACACA)].
- Upregulation of FASN represents a nearly-universal phenotypic alteration in most human malignancies.
- FAs synthesized in cancer cells are esterified predominantly to phospholipids and incorporated into membrane lipids by proliferating cells.
- Many of the genes that encode the enzymes of the FA biosynthetic pathway, including ACLY, ACACA, FASN, reside on human chromosome 17q. This is a common site for gene rearrangement and is the location of many oncogene amplifications. However, only one study evaluating the correlation of the expression levels of lipogenic enzymes with gene copy number alterations has detected a significant increase in FASN copy number in prostate cancer.
- Increased FA synthesis in tumor cells seems to involve the modulation of multiple lipogenic enzymes at various levels (e.g., increased transcription, enhanced protein stabilization).

B




Increased lipogenesis promotes development of human hepatocellular carcinoma (HCC)


NL, normal liver
SL, surrounding liver
HCCB, HCC with better outcome
HCCP, HCC with poor outcome



Stepwise development of hepatocarcinogenesis in AKT-overexpressing mice



Stepwise development of hepatocarcinogenesis in AKT-overexpressing mice



Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia

Suman K. Das,¹ Sandra Eder,² Silvia Schauer,¹ Clemens Diwoky,³ Hannes Temmel,¹ Barbara Guertl,¹ Gregor Gorkiewicz,¹ Kuppusamy P. Tamilarasan,¹ Pooja Kumari,^{1,4} Michael Trauner,⁴ Robert Zimmermann,² Paul Vesely,¹ Guenter Haemmerle,² Rudolf Zechner,^{2*} Gerald Hoefler^{1*}

Cachexia is a multifactorial wasting syndrome most common in patients with cancer that is characterized by the uncontrolled loss of adipose and muscle mass. We show that the inhibition of lipolysis through genetic ablation of adipose triglyceride lipase (*Atgl*) or hormone-sensitive lipase (*Hsl*) ameliorates certain features of cancer-associated cachexia (CAC). In wild-type C57BL/6 mice, the injection of Lewis lung carcinoma or B16 melanoma cells causes tumor growth, loss of white adipose tissue (WAT), and a marked reduction of gastrocnemius muscle. In contrast, *Atgl*-deficient mice with tumors resisted increased WAT lipolysis, myocyte apoptosis, and proteasomal muscle degradation and maintained normal adipose and gastrocnemius muscle mass. *Hsl*-deficient mice with tumors were also protected although to a lesser degree. Thus, functional lipolysis is essential in the pathogenesis of CAC. Pharmacological inhibition of metabolic lipases may help prevent cachexia.


A transcriptional signature and common gene networks link cancer with lipid metabolism

MCF10A, normal mammary epithelial cells


ER-Src, Src kinase oncoprotein fused to ligand-binding domain of estrogen receptor

TAM, tamoxifen

hTERT, telomerase





hTERT, telomerase
SV40E, small T antigen of Simian virus 40
Ras, Ras oncogene



Common Nodes


AP1	LDL
CDKN1A	MAPK
CEBPA	myc
EGF	NFkB
ERBB2	NR3C1
HIF1A	p53
IFNB1	PDGF
IFNG	PI3K
IL13	sp1
IL1B	TGFB1
IL4	TNF
IL6	
insulin	



A transcriptional signature and common gene networks link cancer with lipid metabolism

- Transcriptional profiling of two isogenic models of transformation identified a gene signature linking cancer with inflammatory and metabolic diseases
- Many drugs used for treatment of diabetes and cardiovascular diseases inhibit transformation and tumor growth.
- Lipid metabolism genes are important for transformation and are upregulated in cancer tissues.
- As in atherosclerosis, oxidized LDL and its receptor OLR1 activate the inflammatory pathway through NF- κ B, leading to transformation.
- OLR1 is important for maintaining the transformed state in diverse cancer cell lines and for tumor growth, suggesting a molecular connection between cancer and atherosclerosis.

Contribution of fatty acid oxidation to cancer cell function





Cholesterol/isoprenoid biosynthesis and cancer

- Cancer cells have a deficient feedback control of HMGCR or increased HMGCR expression, suggesting that dysregulation of the mevalonate pathway might drive malignant transformation
- Statins might exert anticarcinogenic activity, however, the mechanisms do not necessarily involve cholesterol lowering
- Mevalonate is a precursor of several products regulating the cell cycle, including dolichol, geranylgeranyldiphosphate (GGPP) and farnesyldiphosphate (FPP).
- Dolichol has a stimulatory effect on DNA synthesis.
- GGPP and FPP cause isoprenylation of the intracellular G proteins Ras and Rho, which in turn regulate the signal transduction of several membrane receptors crucial for the transcription of genes involved in cell proliferation, differentiation, and apoptosis.


Cholesterol and prostate cancer

- Prostate cancer has a genetic component, though it is not well defined.
- Environmental factors play a large role in prostate cancer risk (e.g., Western diet)
- Epidemiological studies suggest that men with hypercholesterolemia are at increased risk for prostate cancer or late stage, aggressive disease.
- Cholesterol-sensitive mechanisms in prostate cancer progression: cell proliferation, inflammation, steroidogenesis.



Cholesterol and breast cancer development

- Hypercholesterolemia and metabolic syndrome are risk factors for breast cancer.
- The cholesterol metabolite **27-hydroxycholesterol (27-HC)** mimics estrogen in certain tissues. Estrogen-driven breast tumors may rely on 27-HC to grow when estrogen isn't available.
- Aggressive breast tumors have higher levels of CYP27A1, which converts cholesterol into 27-HC. Breast cancer patients with low tumor levels of CYP7B1, an enzyme that breaks down 27-HC, didn't live as long as women with the highest levels.
- 27-HC may play a role in other hormone-driven cancers (e.g. Endometrial cancer).



ER = estrogen receptor